Viridian reports positive phase 1 data for VRDN-008, an FcRn inhibitor
The company said the subcutaneous therapy showed deep IgG reduction and an extended half-life, supporting plans for a pivotal myasthenia gravis trial in mid-2027.
SEC filing
2 stories
The company said the subcutaneous therapy showed deep IgG reduction and an extended half-life, supporting plans for a pivotal myasthenia gravis trial in mid-2027.
SEC filing
Viridian Therapeutics posted third-quarter 2026 results showing early Lumvoa uptake, an on-track elegrobart filing, and upcoming VRDN-292 and VRDN-008 milestones, alongside $955.2 million in cash.
SEC filing